Better meta-analytic methods, but best initial treatment for status epilepticus remains obscure
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The most effective benzodiazepine and route of delivery to use as initial treatment for people in status epilepticus is not clear, despite many small and a few medium and large clinical trials. There are many potential choices of both drug and route. Everybody has their favorite and a reason for their choice. Americans like lorazepam, for which there is a wealth of data, but they consistently underdose it. The British favor midazolam and continental Europeans often choose clonazepam for its favorable pharmacology, but hunger for randomized clinical data to support their preconceived conclusions. Families of people with epilepsy prefer giving agents across the buccal mucosa rather than rectally. Some paramedics like the certainty of an IM injection and others the needleless-ness of an intranasal atomizer. Administrators want to avoid higher-cost preparations and favor agents with long shelf lives without refrigeration. Clinical investigations are typically designed with only one of these aspects in mind. As with the blind men and the elephant (figure), a coherent view of the big picture remains elusive. How, then, are we to best understand the data surrounding this clinical question?
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 1859
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.